NASDAQ:RXDX
Delisted
Prometheus Biosciences Inc Stock News
$199.92
+0 (+0%)
At Close: Sep 14, 2023
Merck's $10.8 Billion Prometheus Deal Has Citi Analysts Bullish
08:56am, Monday, 17'th Apr 2023
Prometheus' PRA023 drug can add 15% to 30% to Merck's long-term earnings once approved, according to Citi analysts.
Why Is Prometheus Biosciences (RXDX) Stock Up 70% Today?
08:43am, Monday, 17'th Apr 2023
Prometheus Biosciences (NASDAQ: RXDX ) stock is on the rise Monday after the company revealed an acquisition deal with Merck (NYSE: MRK ). The deal has Merck offering a total of $10.8 billion to acqu
Prometheus Biosciences, XPeng and State Street are among the stocks on the move
08:10am, Monday, 17'th Apr 2023
Here are some of the biggest movers on Monday:
Merck Offers to Buy Prometheus for $10.8 Billion
09:49pm, Sunday, 16'th Apr 2023
Merck & Co. Inc. has agreed to buy Prometheus Biosciences Inc. for about $10.8 billion. Su Keenan reports on Bloomberg Television.
Merck in Late-Stage Talks to Acquire Prometheus Biosciences
12:01am, Sunday, 16'th Apr 2023
Merck & Co. is in late-stage talks to acquire Prometheus Biosciences Inc., according to people familiar with the matter, a move that could give the big drugmaker promising immune disease treatments.
Prometheus Biosciences to Present at the Oppenheimer 33rd Annual Healthcare Conference
08:30am, Thursday, 09'th Mar 2023
SAN DIEGO, March 09, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, developmen
Prometheus Biosciences, Inc. (RXDX) Reports Q4 Loss, Misses Revenue Estimates
06:49pm, Tuesday, 28'th Feb 2023
Prometheus Biosciences, Inc. (RXDX) delivered earnings and revenue surprises of 1.10% and 6.71%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the
Prometheus Biosciences: Strong Growth
12:07am, Sunday, 26'th Feb 2023
Prometheus Biosciences has strong growth potential. Minimal competition ensures demand for its products.
Prometheus Biosciences to Present at the SVB Securities Global Biopharma Conference
04:00pm, Thursday, 09'th Feb 2023
SAN DIEGO, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development
5 Best and Worst Performing Mid-Cap Stocks in Q4 2022
10:53pm, Thursday, 19'th Jan 2023
Mid-cap stocks are proving to be an attractive investment option over the past few years.
These Were the 5 Best and Worst Performing Mid-Cap Stocks in Dec 2022
10:50pm, Monday, 09'th Jan 2023
Mid-cap companies are fast-growing, young companies that are not as volatile as small-cap and not as stable as large-cap companies.
Prometheus Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
08:30am, Tuesday, 03'rd Jan 2023
SAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, developmen
Prometheus Biosciences CEO on the company's ability to raise capital, get FDA approval
07:27pm, Friday, 09'th Dec 2022
Cramer spoke with Prometheus Biosciences CEO Mark McKenna on Friday.
Is Prometheus Biosciences a Good Stock to Buy Right Now?
05:32am, Friday, 09'th Dec 2022
This biotech stock just jumped over 180% in a single day, and investors want to know if there could be more big gains ahead.
Prometheus Biosciences A Buy On Positive Phase 2 Data
03:26pm, Thursday, 08'th Dec 2022
On December 7, Prometheus Biosciences, Inc. announced positive Phase 2 data for PRA023. Prometheus also announced a proposed Public Offering.
